Skip to content
Samrat Pharmachem logo

Samrat Pharmachem

530125 BSE
₹268.00

Close ·

P/E
Not meaningful: loss-making over the last twelve months
View as Markdown
MCP
Close 4 Nov 2026 ₹268.00 −12.15 −4.34% 1Y
Start ₹280.15

Key Fundamentals

MicrocapPharmaceuticals & BiotechnologyHealthcare

Price-based figures at the close · EPS basis: Standalone · TTM

ROCE
−2.88%
Debt to Equity
0.16
EPS (TTM)
−₹7.15
Book Value
₹220.67
Market Cap
—
P/E (TTM)
Not meaningful: loss-making over the last twelve months
P/B
1.21
ROE
−5.19%
Dividend Yield
0.39%
EBITDA
−₹1.30 Cr
52W High
₹298.00
52W Low
₹190.00

Tapetide Score

Data-driven rating, 0–100, as of . How it works →

Overall score

58 Good

Data confidence 91/100

Category scores

Quality
60
Good
Returns, margins, earnings quality 22% weight
Valuation
69
Strong
Cheap vs sector & own history 24% weight
Growth
44
Weak
Sales & profit trajectory 9% weight
Financial Health
37
Poor
Solvency, leverage, coverage 9% weight
Momentum
86
Strong
Trend strength, vol-adjusted 12% weight
Ownership
50
Average
FII/DII/promoter flows 24% weight

The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.

Key Insights

Strengths

1
  • Stock is trading at 1.09 times its book value

Weaknesses

3
  • Company has low interest coverage ratio.
  • The company has delivered a poor sales growth of 10.1% over past five years.
  • Company has a low return on equity of 2.15% over last 3 years.

Technical Indicators

Technical signals: verdict and indicator counts
GroupSignalBearishNeutralBullish
OverallStrong Bullish2710
OscillatorsNeutral171
Moving AveragesStrong Bullish109

Key readings

RSI (14)
56.88
Neutral
MACD (12,26,9)
7.77
Bearish
SMA (50)
242.87
Bullish
SMA (200)
226.69
Bullish

As of

Growth Rate

From the financial statements below. 10Y, 5Y, 3Y: compound annual growth to Mar 2026; 1Y: fiscal year to Mar 2026 against Mar 2025; TTM: four quarters to Jun 2026 against Jun 2025.

Revenue

Revenue growth by window
10Y+16.49%
5Y+10.13%
3Y−2.30%
1Y+1.40%
TTM+4.69%

Net profit

Net profit growth by window
10YTurned to loss
5YTurned to loss
3YTurned to loss
1YTurned to loss
TTMTurned to loss

Operating cash flow

Operating cash flow growth by window
10YZero base
5Y+12.47%
3YTurned positive
1YTurned positive
TTM—

TTM: Reported once a year, so there is no trailing-twelve-month figure.

Operating margin· change in pp

Operating margin growth by window
10Y−2.28 pp
5Y−5.72 pp
3Y−8.41 pp
1Y−4.19 pp
TTM−3.24 pp

Revenue by year

Revenue by year, ₹ crore
Mar 2017₹73.00 Cr
Mar 2018₹93.00 Cr
Mar 2019₹111 Cr
Mar 2020₹137 Cr
Mar 2021₹179 Cr
Mar 2022₹222 Cr
Mar 2023₹311 Cr
Mar 2024₹282 Cr
Mar 2025₹286 Cr
Mar 2026₹290 Cr

Net profit by year

Net profit by year, ₹ crore
Mar 2017₹2.00 Cr
Mar 2018₹3.00 Cr
Mar 2019₹2.00 Cr
Mar 2020₹4.00 Cr
Mar 2021₹5.00 Cr
Mar 2022₹17.00 Cr
Mar 2023₹17.00 Cr
Mar 2024₹2.00 Cr
Mar 2025₹7.00 Cr
Mar 2026−₹3.00 Cr

Quarterly Results

₹ Cr
530125 quarterly results, ₹ crore
Particulars Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales
57.48
79.74
61.67
82.68
80.82
70.17
63.66
71.2
75.65
78.87
63.43
71.77
79.76
Expenses
56.71
79.51
61.56
81.32
78.24
66.8
59.48
71.07
75.52
79.23
64.08
73.01
78.87
Operating Profit
0.77
0.23
0.11
1.36
2.58
3.37
4.18
0.13
0.13
−0.36
−0.65
−1.24
0.89
OPM %
1.34%
0.29%
0.18%
1.64%
3.19%
4.8%
6.57%
0.18%
0.17%
−0.46%
−1.02%
−1.73%
1.12%
Other Income
0.36
0.3
0.42
0.3
0.59
0.49
0
−0.11
0.69
0.05
0.4
−0.31
0.99
Interest
0.22
0.13
0.23
0.11
0.19
0.17
0.1
0.22
0.44
0.26
0.13
0.14
0.11
Depreciation
0.16
0.16
0.16
0.16
0.16
0.17
0.17
0.16
0.17
0.18
0.19
0.19
0.19
PBT
0.75
0.24
0.14
1.39
2.82
3.52
3.91
−0.36
0.21
−0.75
−0.57
−1.88
1.58
Tax %
18.67%
175%
−142.86%
0%
26.6%
24.43%
28.9%
11.11%
209.52%
−21.33%
−19.3%
8.51%
44.94%
Net Profit
0.61
−0.19
0.34
1.4
2.07
2.66
2.78
−0.4
−0.23
−0.59
−0.46
−2.04
0.88
EPS (₹)
1.97
−0.61
1.1
4.53
6.7
8.61
9
−1.29
−0.74
−1.91
−1.49
−6.6
2.85

Profit & Loss

₹ Cr
530125 profit and loss, annual, ₹ crore
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
47
63
73
93
111
137
179
222
311
282
286
290
294
Expenses
46
62
69
87
108
131
170
197
287
279
276
292
295
Operating Profit
1
1
4
6
3
7
9
24
24
2
10
−2
−1
OPM %
2.5%
1.9%
5%
6%
2.9%
4.8%
4.8%
11%
8%
0.9%
3.6%
−0.7%
−0.5%
Other Income
0
0
0
0
0
1
0
1
0
1
1
1
1
Interest
1
1
1
1
1
1
1
1
1
1
1
1
1
Depreciation
0
0
0
0
0
0
0
1
1
1
1
1
1
PBT
0
0
3
5
2
6
7
24
23
3
10
−3
−2
Tax %
35%
33%
37%
35%
29%
27%
27%
27%
26%
14%
28%
11%
—
Net Profit
0
0
2
3
2
4
5
17
17
2
7
−3
−2
EPS (₹)
1.04
0.97
5.66
10.42
4.98
13.72
17.25
55.6
53.82
6.99
23.01
−10.71
−7.15
Div. Payout %
0%
0%
0%
0%
0%
0%
0%
2%
2%
14%
4%
0%
—

Balance Sheet

₹ Cr
530125 balance sheet, annual, ₹ crore
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
3
3
3
3
3
3
3
3
3
3
3
3
Reserves
10
11
12
15
17
21
27
44
60
62
69
65
Borrowings
3
6
7
9
7
9
9
8
19
8
10
11
Other Liabilities
10
17
14
13
14
25
19
30
35
48
40
46
Total Liabilities
26
36
36
41
40
58
57
85
117
122
122
124
Fixed Assets
7
7
7
7
7
7
9
10
11
11
10
12
CWIP
0
0
0
0
0
1
0
0
0
0
0
1
Investments
0
2
0
0
0
0
0
0
2
3
4
4
Other Assets
19
27
29
34
33
50
48
75
104
108
107
108
Total Assets
26
36
36
41
40
58
57
85
117
122
122
124

Cash Flow

₹ Cr
530125 cash flow, annual, ₹ crore
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
−1
0
−3
0
2
−1
5
17
−9
9
−10
9
Investing
0
−2
1
−2
2
−2
−3
−1
−3
0
0
−3
Financing
0
2
1
2
−4
2
−2
−2
10
−11
0
0
Net Cash Flow
0
0
−1
−1
1
−1
0
14
−3
−2
−10
6
Free Cash Flow
−1
−1
−4
0
2
−3
3
16
−11
9
−11
6
CFO/OP
−29
−25
−73
17
126
−7
81
78
0
503
−84
−493

Ratios

530125 financial ratios, annual
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
74
93
59
86
69
74
67
72
61
90
72
64
Inventory Days
38
37
41
31
28
55
25
24
43
28
52
56
Days Payable
76
104
43
46
45
67
39
45
42
65
53
55
Cash Conversion Cycle
36
26
58
70
52
61
53
51
62
53
71
65
Working Capital Days
19
14
34
32
37
39
36
32
40
47
68
52
ROCE %
7%
5%
16%
23%
12%
22%
24%
52%
35%
3%
13%
−3%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Samrat Pharmachem insights

65 extracted metrics across FY11–FY27.

Shareholding Pattern

As of Sep 2026

  • Promoters 49.09%
  • Public 41.79%
  • Others 5.88%
  • FIIs 3.24%

No promoter shares pledged as of 14 Oct 2026

Change vs previous quarter

Not shown for some quarters: Others. Not available separately for this quarter: the shareholding filing gives Public and Others as one figure, shown under Public, so Others is left blank rather than estimated.

Documents

Frequently Asked Questions about Samrat Pharmachem

What does Samrat Pharmachem Ltd do?
Incorporated in 1992, Samrat Pharmachem Ltd does manufacturing and selling of chemicals
Where is Samrat Pharmachem Ltd (SAMRATPH) listed?
Samrat Pharmachem Ltd trades under code 530125 on the BSE.
Which sector does Samrat Pharmachem Ltd belong to?
Samrat Pharmachem Ltd is classified under the Healthcare sector, in the Pharmaceuticals industry.
What is the 52-week high and low of Samrat Pharmachem Ltd?
Over the last 52 weeks Samrat Pharmachem Ltd has traded between ₹190 and ₹298 as of 4 Nov 2026.
Does Samrat Pharmachem Ltd pay dividends?
Samrat Pharmachem Ltd has a dividend yield of 0.39%.
What is the Return on Equity (ROE) of Samrat Pharmachem Ltd?
Samrat Pharmachem Ltd reported a return on equity of -5.19%. Its debt-to-equity ratio is 0.16.

Company Information

Incorporated in 1992, Samrat Pharmachem Ltd does manufacturing and selling of chemicals

Website samratpharmachem.com
Face Value ₹10

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/530125.md for Samrat Pharmachem Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our Indian stock market MCP server.

Explore More

More Pharma stocks → FII DII DataStock ScreenerNifty 50 HeatmapF&O Ban ListFII and DII flows, month by monthHow Tapetide Scores changed, month by monthStocks mutual funds are buying, month by month